Table 2 Association of rs8004379 with BCR in localized prostate cancer patients treated with RP.
From: Genetic variants in ultraconserved regions associate with prostate cancer recurrence and survival
SNP Genotype | Discovery | Replication | Combined | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
No BCR, n (%) | BCR, n (%) | HR (95% CI)a | P a | No BCR, n (%) | BCR, n (%) | HR (95% CI)a | P a | HR (95% CI)a | P a | |
rs8004379 | ||||||||||
AA | 74 (43.3) | 45 (60.0) | 1.00 | 42 (41.6) | 54 (50.9) | 1.00 | 1.00 | |||
AC | 77 (45.0) | 23 (30.7) | 0.52 (0.31–0.90) | 0.018 | 44 (43.6) | 46 (43.4) | 0.78 (0.52–1.18) | 0.241 | 0.67 (0.49–0.92) | 0.01 |
CC | 20 (11.7) | 7 (9.3) | 0.47 (0.20–1.14) | 0.096 | 15 (14.9) | 6 (5.7) | 0.40 (0.17–0.94) | 0.035 | 0.43 (0.24–0.79) | 0.007 |
AC/CC vs AA | 0.51 (0.31–0.84) | 0.008 | 0.70 (0.47–1.05) | 0.083 | 0.62 (0.45–0.84) | 0.002 | ||||
CC vs AA/AC | 0.62 (0.26–1.47) | 0.278 | 0.45 (0.20–1.04) | 0.061 | 0.52 (0.29–0.95) | 0.03 | ||||
Trend | 0.61 (0.41–0.91) | 0.015 | 0.70 (0.51–0.96) | 0.027 | 0.66 (0.52–0.85) | 0.001 | ||||
